Xianjun Yu
Fudan University · Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center Shanghai, Shanghai, China · 270 Dong An Road, Shanghai 200032, China
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
23
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
NIH RePORTER
Trial papers in pancreatic cancer
18
PubMed author-name match
Trials
Studies that name Xianjun Yu as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:09 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07868172 · GST101 in Participants With RAS-Mutant Advanced Solid TumorsGenuine Seed Therapeutics (Zhuhai) Co., Ltd. · recruiting · RAS-mutant Advanced Solid Tumors · study chair
- Ph1NCT07718165 · A Phase I Study of ABSK211 in Participants With Advanced Solid Tumors With KRAS AlterationAbbisko Therapeutics Co, Ltd · recruiting · Solid Tumor (Phase I) · principal investigator
- N/ANCT07592663 · Oncologic Safety and Lymphadenectomy in Parenchyma-Sparing Resection for SPNFudan University · completed · Pancreatic Tumor, Benign, Solid Pseudopapillary Tumor of the Pancreas · principal investigator
- Ph1/Ph2NCT07417189 · A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )Abbisko Therapeutics Co, Ltd · recruiting · Solid Tumors, Adult · principal investigator
- Ph3NCT07138846 · A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic CancerLepu Biopharma Co., Ltd. · not yet recruiting · Advanced Pancreatic Cancer · principal investigator
- N/ANCT06790355 · ProSight: A Multi-centre Interventional Study Evaluating MCED in Asymptomatic PopulationShanghai Weihe Medical Laboratory Co., Ltd. · completed · Lung Cancer, Colorectal Cancer, Liver Cancer · principal investigator
- N/ANCT06557408 · Pancreatic Fistula After Minimally Invasive EnucleationFudan University · completed · Pancreatic Tumor, Benign, Pancreatic Neuroendocrine Tumor, Solid Pseudopapillary Tumor of the Pancreas · principal investigator
- Ph2NCT06492915 · Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal AdenocarcinomaChipscreen Biosciences, Ltd. · active not recruiting · Pancreatic Ductal Adenocarcinoma · principal investigator
- N/ANCT06167421 · Comparison of Kimura Versus Warshaw Technique for Laparoscopic Spleen-Preserving Distal PancreatectomyFudan University · not yet recruiting · Pancreatic Tumor, Benign, Pancreatic Neuroendocrine Tumor, Solid Pseudopapillary Tumor of the Pancreas · principal investigator
- N/ANCT06024343 · Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Exposure, Repair or ReconstructionFudan University · completed · Pancreatic Tumor, Benign, Pancreatic Neuroendocrine Tumor, Solid Pseudopapillary Tumor of the Pancreas · principal investigator
- N/ANCT05939063 · LRAMPS Versus LDP in Selected Early-stage Left-sided Pancreatic CancerFudan University · recruiting · Left-sided Pancreatic Cancer · principal investigator
- Ph1NCT05911217 · A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic CancerCARsgen Therapeutics Co., Ltd. · recruiting · Pancreatic Cancer · principal investigator
- N/ANCT05907824 · Long-term Prognosis for Non-functional Neuroendocrine Tumors of the Pancreatic Body and Tail ≤ 3cmFudan University · unknown · Non Functioning Pancreatic Endocrine Tumor · principal investigator
- N/ANCT05847855 · Plasma cfDNA Fragmentomics for Early pNET Detection and Differential Diagnosis of Solid Pancreatic TumorsFudan University · recruiting · Pancreatic Neuroendocrine Tumor, Solid Pancreatic Neoplasms · principal investigator
- Ph1NCT05707676 · A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LB4330 in Patients With Advanced Solid Tumors（MEETCD8-001）L & L Bio Co., Ltd., Ningbo, China · terminated · Solid Tumor · principal investigator
- N/ANCT04931446 · Neuroendocrine Neoplasm Based on Multi-omics Integrated AnalysisXian-Jun Yu · unknown · Neuroendocrine Neoplasm · principal investigator
- N/ANCT04927611 · Single-cell Sequencing and Establishment of Models in Neuroendocrine NeoplasmFudan University · unknown · Neuroendocrine Neoplasm · principal investigator
- Ph1NCT04893759 · A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine TumorsAscentage Pharma Group Inc. · terminated · Neuroendocrine Tumors · principal investigator
- N/ANCT04855331 · Laparoscopic Versus Open Pancreatoduodenectomy Following Neoadjuvant Chemotherapy for BRPCFudan University · unknown · Borderline Resectable Pancreatic Cancer · principal investigator
- Ph1/Ph2NCT04581473 · Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell InjectionCARsgen Therapeutics Co., Ltd. · active not recruiting · Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma · principal investigator
- Ph1/Ph2NCT04228601 · A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic CancerJiangsu HengRui Medicine Co., Ltd. · completed · Advanced Pancreatic Cancer · principal investigator
- Ph2NCT03403101 · The Combination Chemotherapy of SIRIOX as First- or Second-Line Chemotherapy for Pancreatic CancerFudan University · unknown · Carcinoma, Pancreatic Ductal · study chair
- Ph2NCT02005419 · Metformin Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative ResectionXian-Jun Yu · completed · Stage IA Pancreatic Adenocarcinoma, Stage IB Pancreatic Adenocarcinoma, Stage IIA Pancreatic Adenocarcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:09 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in pancreatic cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:09 UTC. The ranking covers the 200 most relevant of 18 PubMed records, and a shared surname and initials can bring in a namesake. All 18 on PubMed
- Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study.Lancet Oncol · 2020182 citationsRCR 7.2
- Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study.Lancet Oncol · 2020176 citationsRCR 6.8
- Concurrent gemcitabine and high-intensity focused ultrasound therapy in patients with locally advanced pancreatic cancer.Anticancer Drugs · 201088 citationsRCR 2.5
- Neurolytic Splanchnic Nerve Block and Pain Relief, Survival, and Quality of Life in Unresectable Pancreatic Cancer: A Randomized Controlled Trial.Anesthesiology · 202134 citationsRCR 2.1
- Standard pancreatoduodenectomy versus extended pancreatoduodenectomy with modified retroperitoneal nerve resection in patients with pancreatic head cancer: a multicenter randomized controlled trial.Cancer Commun (Lond) · 202331 citationsRCR 2.7
- 20 citationsRCR 1.0
- Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma.Chin Med J (Engl) · 200919 citationsRCR 0.4
- Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study.BMC Cancer · 201712 citationsRCR 0.4
- 7 citationsRCR 2.3
- A phase 1b/2 study of first-line anti-PD-L1/ TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitabine for advanced pancreatic ductal adenocarcinoma.Signal Transduct Target Ther · 20257 citationsRCR 1.3